A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer

Official Title

The Evaluation of Hypoxia Imaging in Patients With Pancreatic Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)

Summary:

This is a diagnostic study to look for low levels of oxygen (hypoxia) in pancreatic cancer using an imaging test called positron emission tomography (PET). Hypoxia can influence how pancreatic cancer grows and responds to treatments such as chemotherapy and radiation therapy. The use of PET scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET scans using a tracer called 18F-FAZA (18F-Fluoroazomycin Arabinoside) can provide useful information about hypoxia in pancreatic cancer. Also as part of the study, a blood sample will be taken to study biomarkers (substances in the body that may be important indicators of hypoxia and/or pancreatic cancer) that may be useful in studying pancreatic cancer and hypoxia.

Trial Description

Primary Outcome:

  • Measure the hypoxia level in Patients with Pancreatic Cancer using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA).
Secondary Outcome:
  • Correlate FAZA PET uptake in pancreatic cancer with the extension of the disease.
  • Correlate FAZA PET uptake in pancreatic cancer with CA 19-9 levels.
  • Correlate FAZA PET uptake in pancreatic cancer with tumour response.
  • Correlate FAZA PET uptake in pancreatic cancer with patient disease-free survival (DFS).
  • Compare the pattern of FAZA uptake in different tumour sites (eg., lymph node metastases and liver metastasis).
  • Determine the feasibility of using dynamic and static PET imaging of FAZA uptake in patients with pancreatic cancer.
This is a single centre, single arm hypoxia study of pancreatic cancer with PET FAZA imaging. PET-CT imaging of tumour hypoxia with FAZA will be done prior to the start of standard treatment for pancreatic cancer with chemotherapy. The FAZA PET-CT imaging session will last approximately 2.5 hours and include an initial dynamic scan to completely characterize the initial rapid phase of FAZA uptake, followed by a later static scan.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society